Clinical Trials Logo

Meningococcal Infection clinical trials

View clinical trials related to Meningococcal Infection.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06128733 Recruiting - Healthy Volunteers Clinical Trials

Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents

Start date: October 31, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of VAN00010 study is to assess the safety and immunogenicity of the investigational pentavalent meningococcal ABCYW vaccine in adults and adolescents. The study duration will be up to 12 months for all participants.

NCT ID: NCT05929651 Recruiting - Healthy Volunteers Clinical Trials

Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy

Start date: September 7, 2023
Phase: Phase 4
Study type: Interventional

This study will evaluate the immunogenicity and safety of a single dose of MenQuadfi® administered as a booster vaccine in toddlers 12 - 23 months of age in Argentina who had been primed with at least 1 dose of the quadrivalent meningococcal conjugate vaccines Nimenrix® or Menveo® during infancy to protect against invasive meningococcal disease (IMD). Participants will receive a single dose of MenQuadfi® at Visit 1. Participants will provide 2 blood samples, one at D01 (Visit 1) pre-vaccination and another at D31 (Visit 2) post-vaccination for the immunogenicity assessments. Study will include 2 visits at D01 (Visit 1) and at D31 (Visit 2), and 1 Telephone call (TC) for safety follow-up at D09 post-study vaccination.

NCT ID: NCT04843111 Recruiting - Clinical trials for Meningococcal Infection

Observational, Passive Surveillance Program to Collect Information on Women and Their Offspring Exposed to MenQuadfi® During Pregnancy, in United States (US)

Start date: March 5, 2021
Phase:
Study type: Observational [Patient Registry]

Primary Objective: To assess maternal, obstetrical, pregnancy, and neonatal and infant outcomes among women vaccinated with MenQuadfi® during pregnancy or in the 30 days preceding their Last Menstrual Period (LMP).